Amputations under PMB Regulations: The Latest CMScript

By HEOR Staff Writer

January 20, 2023

Council for Medical Schemes latest CMScript focusing on amputations under PMB regulations. Amputation, the removal or loss of a body part, can drastically alter a person’s life. It impacts an individual’s mobility, work capabilities, social interactions, and independence. This article explores the causes of amputations, preventative measures, and the journey towards recovery and rehabilitation.

Life After Amputation: Recovery and Rehabilitation

Amputations due to traumatic and crush injuries, severe burns, diabetes mellitus, peripheral artery diseases, severe infections, and cancers must be funded in line with the PMB Regulations. This would include diagnosis, treatment, and care of PMBs irrespective of the member’s option.

Prosthetic limbs replace the function of the lost body part and are recommended based on the type of amputation, the patient’s general health, and the tasks expected to be performed using the prosthesis. However, not all individuals are suitable for a prosthetic limb, particularly those with serious health conditions such as heart failure.

Preventing Amputations

Preventing amputations involves addressing the underlying issues that may necessitate such a procedure. Lifestyle modifications, including a balanced diet, regular exercise, quitting smoking, and maintaining stable blood sugar, blood pressure, and cholesterol levels, are essential. Regular examination of the legs and feet for sores or changes in skin colour or temperature is also crucial.

Reference url

Recent Posts

Aspen Pharmacare Financial Growth: Navigating H1 2026’s Transitional Financial Landscape

By HEOR Staff Writer

March 5, 2026

Aspen Pharmacare Financial Growth Powers Through Strategic Shifts Aspen Pharmacare's financial growth shines in its H1 2026 results, driven by resilient Commercial Pharmaceuticals,
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Prevention
South Africa has launched a bold bid to enable local lenacapavir production, targeting the twice-yearly injectable long-acting HIV prevention drug from ...
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a